Logo image of VCEL

VERICEL CORP (VCEL) Stock Fundamental Analysis

NASDAQ:VCEL - US92346J1088 - Common Stock

33.67 USD
+0.12 (+0.36%)
Last: 9/4/2025, 8:00:02 PM
32.8 USD
-0.87 (-2.58%)
After Hours: 9/4/2025, 8:00:02 PM
Fundamental Rating

6

Overall VCEL gets a fundamental rating of 6 out of 10. We evaluated VCEL against 542 industry peers in the Biotechnology industry. VCEL scores excellent on profitability, but there are some minor concerns on its financial health. VCEL is growing strongly while it is still valued neutral. This is a good combination! These ratings could make VCEL a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

VCEL had positive earnings in the past year.
VCEL had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VCEL reported negative net income in multiple years.
VCEL had a positive operating cash flow in each of the past 5 years.
VCEL Yearly Net Income VS EBIT VS OCF VS FCFVCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

VCEL has a better Return On Assets (1.63%) than 90.04% of its industry peers.
VCEL's Return On Equity of 2.32% is amongst the best of the industry. VCEL outperforms 91.33% of its industry peers.
VCEL has a Return On Invested Capital of 0.24%. This is amongst the best in the industry. VCEL outperforms 89.67% of its industry peers.
Industry RankSector Rank
ROA 1.63%
ROE 2.32%
ROIC 0.24%
ROA(3y)-1.54%
ROA(5y)-1.26%
ROE(3y)-2.18%
ROE(5y)-1.76%
ROIC(3y)N/A
ROIC(5y)N/A
VCEL Yearly ROA, ROE, ROICVCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

VCEL has a Profit Margin of 2.85%. This is amongst the best in the industry. VCEL outperforms 90.41% of its industry peers.
The Operating Margin of VCEL (0.48%) is better than 89.67% of its industry peers.
The Gross Margin of VCEL (73.47%) is better than 82.47% of its industry peers.
VCEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.48%
PM (TTM) 2.85%
GM 73.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y1.27%
VCEL Yearly Profit, Operating, Gross MarginsVCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

5

2. Health

2.1 Basic Checks

VCEL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, VCEL has more shares outstanding
Compared to 5 years ago, VCEL has more shares outstanding
Compared to 1 year ago, VCEL has a worse debt to assets ratio.
VCEL Yearly Shares OutstandingVCEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
VCEL Yearly Total Debt VS Total AssetsVCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

VCEL has an Altman-Z score of 7.65. This indicates that VCEL is financially healthy and has little risk of bankruptcy at the moment.
VCEL has a better Altman-Z score (7.65) than 81.92% of its industry peers.
VCEL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
VCEL's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. VCEL outperforms 45.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 7.65
ROIC/WACC0.02
WACC9.87%
VCEL Yearly LT Debt VS Equity VS FCFVCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 4.97 indicates that VCEL has no problem at all paying its short term obligations.
VCEL has a Current ratio (4.97) which is in line with its industry peers.
A Quick Ratio of 4.56 indicates that VCEL has no problem at all paying its short term obligations.
The Quick ratio of VCEL (4.56) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.56
VCEL Yearly Current Assets VS Current LiabilitesVCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

8

3. Growth

3.1 Past

VCEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 864691128455134976.00%, which is quite impressive.
The Earnings Per Share has been growing slightly by 3.71% on average over the past years.
The Revenue has grown by 16.13% in the past year. This is quite good.
The Revenue has been growing by 15.01% on average over the past years. This is quite good.
EPS 1Y (TTM)864691128455134800%
EPS 3YN/A
EPS 5Y3.71%
EPS Q2Q%90%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y14.95%
Revenue growth 5Y15.01%
Sales Q2Q%20.09%

3.2 Future

The Earnings Per Share is expected to grow by 49.77% on average over the next years. This is a very strong growth
VCEL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.42% yearly.
EPS Next Y24.67%
EPS Next 2Y88.52%
EPS Next 3Y80.79%
EPS Next 5Y49.77%
Revenue Next Year15.49%
Revenue Next 2Y18.93%
Revenue Next 3Y20.19%
Revenue Next 5Y22.42%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VCEL Yearly Revenue VS EstimatesVCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
VCEL Yearly EPS VS EstimatesVCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 280.58, the valuation of VCEL can be described as expensive.
89.85% of the companies in the same industry are more expensive than VCEL, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.03, VCEL is valued quite expensively.
A Price/Forward Earnings ratio of 52.64 indicates a quite expensive valuation of VCEL.
89.67% of the companies in the same industry are more expensive than VCEL, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of VCEL to the average of the S&P500 Index (22.63), we can say VCEL is valued expensively.
Industry RankSector Rank
PE 280.58
Fwd PE 52.64
VCEL Price Earnings VS Forward Price EarningsVCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

VCEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VCEL is cheaper than 89.48% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 162.76
VCEL Per share dataVCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of VCEL may justify a higher PE ratio.
A more expensive valuation may be justified as VCEL's earnings are expected to grow with 80.79% in the coming years.
PEG (NY)11.37
PEG (5Y)75.55
EPS Next 2Y88.52%
EPS Next 3Y80.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VCEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERICEL CORP

NASDAQ:VCEL (9/4/2025, 8:00:02 PM)

After market: 32.8 -0.87 (-2.58%)

33.67

+0.12 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners111.03%
Inst Owner Change0.45%
Ins Owners1.04%
Ins Owner Change1.2%
Market Cap1.70B
Analysts87.14
Price Target54.95 (63.2%)
Short Float %11.28%
Short Ratio9.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.99%
Min EPS beat(2)-78.61%
Max EPS beat(2)68.63%
EPS beat(4)3
Avg EPS beat(4)16.25%
Min EPS beat(4)-78.61%
Max EPS beat(4)68.63%
EPS beat(8)6
Avg EPS beat(8)20.38%
EPS beat(12)8
Avg EPS beat(12)32.28%
EPS beat(16)8
Avg EPS beat(16)-1.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.04%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)-3.86%
Revenue beat(4)1
Avg Revenue beat(4)-2.16%
Min Revenue beat(4)-4.23%
Max Revenue beat(4)2.84%
Revenue beat(8)2
Avg Revenue beat(8)-1.28%
Revenue beat(12)4
Avg Revenue beat(12)-0.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.44%
PT rev (1m)-7.91%
PT rev (3m)-14.82%
EPS NQ rev (1m)-112.19%
EPS NQ rev (3m)-114.42%
EPS NY rev (1m)-10.2%
EPS NY rev (3m)-10.2%
Revenue NQ rev (1m)-8.72%
Revenue NQ rev (3m)-7.38%
Revenue NY rev (1m)-3.8%
Revenue NY rev (3m)-3.8%
Valuation
Industry RankSector Rank
PE 280.58
Fwd PE 52.64
P/S 6.82
P/FCF N/A
P/OCF 35.97
P/B 5.54
P/tB 5.65
EV/EBITDA 162.76
EPS(TTM)0.12
EY0.36%
EPS(NY)0.64
Fwd EY1.9%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)0.94
OCFY2.78%
SpS4.94
BVpS6.08
TBVpS5.96
PEG (NY)11.37
PEG (5Y)75.55
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 2.32%
ROCE 0.3%
ROIC 0.24%
ROICexc 0.34%
ROICexgc 0.35%
OM 0.48%
PM (TTM) 2.85%
GM 73.47%
FCFM N/A
ROA(3y)-1.54%
ROA(5y)-1.26%
ROE(3y)-2.18%
ROE(5y)-1.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y1.27%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.17
Cap/Depr 667.96%
Cap/Sales 22.3%
Interest Coverage 250
Cash Conversion 496.85%
Profit Quality N/A
Current Ratio 4.97
Quick Ratio 4.56
Altman-Z 7.65
F-Score7
WACC9.87%
ROIC/WACC0.02
Cap/Depr(3y)649.08%
Cap/Depr(5y)464.88%
Cap/Sales(3y)15.17%
Cap/Sales(5y)10.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)864691128455134800%
EPS 3YN/A
EPS 5Y3.71%
EPS Q2Q%90%
EPS Next Y24.67%
EPS Next 2Y88.52%
EPS Next 3Y80.79%
EPS Next 5Y49.77%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y14.95%
Revenue growth 5Y15.01%
Sales Q2Q%20.09%
Revenue Next Year15.49%
Revenue Next 2Y18.93%
Revenue Next 3Y20.19%
Revenue Next 5Y22.42%
EBIT growth 1Y131.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2048.47%
EBIT Next 3Y242.91%
EBIT Next 5Y173.2%
FCF growth 1Y-161.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.11%
OCF growth 3Y26.05%
OCF growth 5YN/A